Identification of SARS-CoV-2-specific immune alterations in acutely ill patients
- J Clin Invest. 2021 Apr 15;131(8):e145853. doi: 10.1172/JCI145853.
- 1. Department of Neuroscience, Université de Montréal, Montreal, Quebec, Canada.
- 2. Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada.
- 3. Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada.
- 4. Department of Microbiology, Infectious Diseases and Immunology, and.
- 5. Department of Medicine, Université de Montréal, Montreal, Quebec, Canada.
Dysregulated immune profiles have been described in symptomatic patients infected with SARS-CoV-2. Whether the reported immune alterations are specific to SARS-CoV-2 Infection or also triggered by Other acute illnesses remains unclear. We performed flow cytometry analysis on fresh peripheral blood from a consecutive cohort of (a) patients hospitalized with acute SARS-CoV-2 Infection, (b) patients of comparable age and sex hospitalized for another acute disease (SARS-CoV-2 negative), and (c) healthy controls. Using both data-driven and hypothesis-driven analyses, we found several dysregulations in immune cell subsets (e.g., decreased proportion of T cells) that were similarly associated with acute SARS-CoV-2 Infection and non-COVID-19-related acute illnesses. In contrast, we identified specific differences in myeloid and lymphocyte subsets that were associated with SARS-CoV-2 status (e.g., elevated proportion of ICAM-1+ mature/activated neutrophils, ALCAM+ monocytes, and CD38+CD8+ T cells). A subset of SARS-CoV-2-specific immune alterations correlated with disease severity, disease outcome at 30 days, and mortality. Our data provide an understanding of the immune dysregulation specifically associated with SARS-CoV-2 Infection among acute care hospitalized patients. Our study lays the foundation for the development of specific biomarkers to stratify SARS-CoV-2-positive patients at risk of unfavorable outcomes and to uncover candidate molecules to investigate from a therapeutic perspective.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Biochemical Assay ReagentsResearch Areas: Others